Polypegylated recombinant human interleukin-2

多聚乙二醇化重组人白介素-2

Report date: 2022/06/20 20:00:35

Base Information

Drug NamePolypegylated recombinant human interleukin-2
Drug Alias Name8MW23118-MW23118MW-23118-MW-2311
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Renal CellMelanoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsCarcinoma, Renal CellMelanomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A